Switzerland· 68373002
Idefirix 11 mg, poudre pour solution à diluer pour perfusion
A imlifidase product containing imlifidasum, registered in Switzerland by IQONE HEALTHCARE SWITZERLAND SA and dispensed under Swissmedic category A. The same ATC class is registered in 12 of our 19 countries.
Checked against Swissmedic (Switzerland) on
Informational only — not a medical device.
Where it is registered
Imlifidase is registered in 12 of 19 countries.
Countries holding a registration under ATC L04AA41 (imlifidase), each read from that country’s own register.
- This record: Switzerland, from Swissmedic (Switzerland)
- 8 of them publish a price we can compare per daily dose
Imlifidase · ATC L04AA41
12 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
Price per daily dose
What a daily dose of imlifidase costs, country by country.
Normalised to the WHO defined daily dose (17.5 mg), so markets compare like for like.
- Switzerland: $271803.14 per daily dose (median across products in the class)
- Public list prices, converted to USD at the rate date shown
Imlifidase · price per daily dose (17.5 mg)
USD · FX 28 Sept 2026
- CH Switzerland$271803.14
The record
At a glance
Swissmedic (Switzerland)- Active substance
- imlifidasum
- Manufacturer
- IQONE HEALTHCARE SWITZERLAND SA
- Country
- Switzerland (CH)
- ATC code
- L04AA41
- ATC class
- Imlifidase
- Defined daily dose
- 17.5 mg, P
- Swissmedic category
- A
- Reimbursed
- No
- Source register
- Swissmedic (Switzerland)
- Last checked
- September 12, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Imlifidase in 12 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaIDEFIRIXHansa Biopharma AB, Lund
- SpainIDEFIRIX 11 MG DE POLVO PARA CONCENTRADO PARA SOLUCION PARA PERFUSIONHansa Biopharma Ab
- FinlandIdefirixHansa Biopharma AB
- United KingdomIdefirix 11mg powder for concentrate for solution for infusion vialsHansa Biopharma AB
- IrelandIdefirix 11 mg powder for concentrate for solution for infusionHansa Biopharma AB
- IcelandIdefirixHansa Biopharma AB
- NorwayIdefirixHansa Biopharma AB
- PolandIdefirixHansa Biopharma AB
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Idefirix
- Liechtenstein · Idefirix
- Norway · Idefirix
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Swissmedic (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/40eb85b5-9cac-4fe2-b392-fda49476d63a GET /v1/drugs/40eb85b5-9cac-4fe2-b392-fda49476d63a?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{}See everything about imlifidase.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.